ut-logo website  
 
Log in
Express registration and login!
If you have a Facebook or LinkedIN account, use one of the buttons on the left to either login or create a new account.

Log in

 

You are here:
Home

Enzalutamide:

1. Treatment of Castration Resistant Prostate Cancer
... and postdocetaxel settings. Targeted Therapies-Androgen Receptor Modulation Enzalutamide (formerly MDV3100) is an investigational therapy in Phase 3 clinical development. Enzalutamide is the ...
2. FDA approves Xtandi (enzalutamide)
SILVER SPRING, MD USA (PRESS RELEASE) - August 31, 2012 The U.S. Food and Drug Administration today approved Xtandi (enzalutamide) to treat men with late-stage (metastatic) castration-resistant prostate ...
3. GU Cancers Symposium 2013 - Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor, by Howard I. Scher, MD - Session Highlights
ORLANDO, FL, USA (UroToday.com) - Enzalutamide (ENZA) is a novel androgen receptor (AR) and AR signaling inhibitor. In the AFFIRM study, ENZA increased median overall survival (OS) by 4.8 months vs. placebo ...
4. GU Cancers Symposium 2013 - Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer, by Bertrand Tombal, MD, PhD, et al. - Session Highlights
ORLANDO, FL, USA (UroToday.com) - Androgen deprivation therapy (ADT) has been the standard-of-care treatment for advanced prostate cancer for a long time.
5. SES AUA 2013: Session Highlights - Management of castration resistant prostate cancer (CRPC): Update of new treatments
WILLIAMSBURG, VA USA (UroToday.com) - Dr. Stephen Freedland begun this session by defining CRPC, and he stressed castrate resistant, meaning the patient must have testosterone levels (T) lower than the ...
6. AUA releases new guidelines for treating castration-resistant prostate cancer
SAN DIEGO, CA USA (Press Release) - May 6, 2013 - Urges providers to incorporate patient treatment goals, preferences and personal goals
7. AUA 2013 - Session Highlights: AUA Guidelines: Castration Resistant Prostate Cancer
SAN DIEGO, CA USA (UroToday.com) - Michael Cookson, MD, Vice Chair and Professor of Urologic Surgery at Vanderbilt, presented the first AUA guideline for the management of castration-resistant prostate ...